
To the Editor:

The study by Sanborn et al1 is a post hoc analysis in which multiple statistical tests have been made in an exploratory manner to examine the possible differences in access-site bleeding (ASB) with or without a vascular closure device (VCD). If *P* values <0.05 are used for statistical significance, a high false discovery rate for significant differences is to be expected.

Patients with a major ASB were allotted to 7 end-point subgroups, but the sum of the patients in the subgroups is greater than the total number with major ASB. Therefore, many patients have been allotted to several subgroups and included in several analyses.

The only end-point subgroup comparison showing a significant difference was the ≥5-cm-diameter hematoma end point, inconsequential concerning the need for intervention or surgical correction. The difference between the VCD and the no-VCD groups concerning requirement for interventional or surgical correction of ASB, with a *P* value of 0.048, may be because of chance.

Patients who did not receive a VCD may have been more prone to develop an ASB because of a higher rate of hypertension and renal insufficiency. They may have received more intense platelet inhibition because of a higher rate of elevated biomarkers, and their higher rate of anemia may have increased the likelihood of intervention because of hemorrhage.

VCD complications can result in permanent tissue malfunction or loss and severe infections.2-3 There is no proof to support the belief of the authors that contemporary VCD complication rates are decreasing. A realistic VCD complication rate on the order of 1:275 among the 4307 patients would result in 16 complications, most of them far more serious than the 16 ASBs in their study, requiring interventional, presumably transfusions, or surgical correction.3,4 In addition, late undetected complications may occur.2

The use of a VCD has not been demonstrated to improve survival. In contrary, their use has been followed by serious complications. Although bleeding is a predictor of 30-day mortality in invasively managed patients, the implied assumption that VCD use can reduce the mortality is presently unfounded.

Some of the authors may have a vested interest in the performance of firms producing VCDs.

Disclosures

None.

Einar Dregelid, MD
Department of Vascular Surgery
Haukeland University Hospital
Bergen, Norway

References

Letter by Dregelid Regarding Article, "Impact of Femoral Vascular Closure Devices and Antithrombotic Therapy on Access Site Bleeding in Acute Coronary Syndromes: The Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) Trial"

Einar Dregelid

_Circ Cardiovasc Interv._ 2010;3:e12
doi: 10.1161/CIRCINTERVENTIONS.110.954156
_Circulation: Cardiovascular Interventions_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2010 American Heart Association, Inc. All rights reserved.
Print ISSN: 1941-7640. Online ISSN: 1941-7632

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circinterventions.ahajournals.org/content/3/3/e12

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation: Cardiovascular Interventions_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation: Cardiovascular Interventions_ is online at:
http://circinterventions.ahajournals.org//subscriptions/